These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 15972137)

  • 21. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome.
    Cazzola M
    Int J Hematol; 2000 Aug; 72(2):134-8. PubMed ID: 11039660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of patients with myelodysplastic syndrome with amifostine.
    Galanopoulos A; Kritikou-Griva E; Gligori J; Michalis E; Grigoraki V; Marinakis T; Kakkas J; Tasiopoulou A; Anagnostopoulos NI
    Leuk Res; 2001 Aug; 25(8):665-71. PubMed ID: 11397471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes.
    Stein RS; Abels RI; Krantz SB
    Blood; 1991 Oct; 78(7):1658-63. PubMed ID: 1912554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.
    Stasi R; Brunetti M; Bussa S; Conforti M; Di Giulio C; Crescenzi A; Terzoli E; Vecchione A; Pagano A
    Clin Cancer Res; 1997 May; 3(5):733-9. PubMed ID: 9815743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amifostine promotes hemopoietic progenitor cell mobilization in patients with myelodysplastic syndrome.
    Arboscello E; Botta M; Lerza R; Bogliolo G; Clavio M; Miglino M; Mencoboni M; Pannacciulli I
    Anticancer Res; 2002; 22(3):1819-24. PubMed ID: 12168875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro study of erythropoiesis in patients with aplastic anemia and myelodysplastic syndromes: a possible tool for prospective determination of the clinical effectiveness of growth factors.
    Aoki A; Shibata A
    Hematol Pathol; 1992; 6(3):143-53. PubMed ID: 1429342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes.
    Tsiara SN; Kapsali HD; Panteli K; Christou L; Bourantas KL
    J Exp Clin Cancer Res; 2001 Mar; 20(1):35-8. PubMed ID: 11370827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment.
    Yoshida Y; Anzai N; Kawabata H; Kohsaka Y; Okuma M
    Ann Hematol; 1993 Apr; 66(4):175-80. PubMed ID: 8485205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Erythropoietin treatment of anemia associated with multiple myeloma (MM) and myelodysplastic syndrome (MDS)].
    Qiao ZH
    Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):122-4. PubMed ID: 8223121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of amifostine in a patient with an advanced-stage myelodysplastic syndrome.
    Yilmaz A; Kaufmann CC; Binder C; Wörmann B; Haase D
    Ann Hematol; 2001 Jan; 80(1):53-7. PubMed ID: 11233778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Early effect of amifostine in treating aged patients with idiopathic thrombocytopenia purpura].
    Fan H; Zhu HL; Yao SQ; Lu XC; Zhuang XM; Yang Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):301-3. PubMed ID: 16638202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases.
    Itzykson R; Ayari S; Vassilief D; Berger E; Slama B; Vey N; Suarez F; Beyne-Rauzy O; Guerci A; Cheze S; Thomas X; Stamatoullas A; Gardembas M; Bauduer F; Kolb A; Chaury MC; Legros L; Damaj G; Chermat F; Dreyfus F; Fenaux P; Ades L;
    Leukemia; 2009 Apr; 23(4):673-8. PubMed ID: 19151787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study.
    Di Raimondo F; Longo G; Cacciola E; Milone G; Palumbo GA; Cacciola RR; Alessi M; Giustolisi R
    Eur J Haematol; 1996; 56(1-2):7-11. PubMed ID: 8599997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis.
    Balleari E; Filiberti RA; Salvetti C; Allione B; Angelucci E; Bruzzone M; Calzamiglia T; Cavaliere M; Cavalleri M; Cilloni D; Clavio M; Crisà E; Da Col A; Danise P; Pilo F; Ferrero D; Finelli C; Gioia D; Lemoli RM; Masiera E; Messa E; Miglino M; Musto P; Natalie Oliva E; Poloni A; Salvi F; Sanna A; Scudeletti M; Tassara R; Santini V
    Cancer Med; 2019 Dec; 8(18):7567-7576. PubMed ID: 31657156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia.
    Bessho M; Jinnai I; Matsuda A; Saito M; Hirashima K
    Int J Cell Cloning; 1990 Nov; 8(6):445-58. PubMed ID: 2273298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis.
    Mohr B; Herrmann R; Huhn D
    Acta Haematol; 1993; 90(2):65-70. PubMed ID: 8285020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in hemopoietic precursors after treatment of low-risk myelodysplasia with amifostine.
    Ribeiro E; Lima CS; Metze K; Souza CA; Lorand-Metze I
    In Vivo; 2003; 17(2):181-4. PubMed ID: 12792983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
    Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
    Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
    Stasi R; Pagano A; Terzoli E; Amadori S
    Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.